Shares of Biomea Fusion Inc. BMEA jumped 17% in premarket trading Monday after the clinical-stage biopharmaceutical company released new clinical data on its investigational covalent menin inhibitor for patients with type 2 diabetes. The data supports the ability of the treatment, BMF-219, to address a root cause of the disease, beta cell loss, Biomea CEO and chairman Thomas Butler said in a statement. Patients saw an improvement in glycemic control even after dosing of BMF-219 stopped, Butler said. The data were released Friday at the American Diabetes Association’s 83rd Scientific Sessions in San Diego. J.P. Morgan…
